Please be advised that Cytox Limited was placed into Liquidation on 4 January 2024, with Simon Farr and Anthony Collier of FRP Advisory Trading Limited being appointed Joint Liquidators of the Company. If you are owed money by Cytox Limited, or require further information about the Liquidation, please do not hesitate to contact firstname.lastname@example.org.
Mar 20, 2017
Breakthrough studies describing new precision medicine approach for assessing Alzheimer’s disease risk to be presented at AD/PD conference in Vienna
Pioneering approach combines SNP panel with PRS algorithms for identifying true amyloid positive and true amyloid negative individuals in pre-symptomatic and MCI subjects
Oxford, UK. Cytox Ltd, whose mission is to transform treatment decisions for Alzheimer’s disease (AD) by delivering clinically actionable information to assess risk and prediction of developing dementia, has announced that it will be making an oral presentation at the multidisciplinary 13th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2017), 29 March to 2 April in Vienna, Austria. The presentation will share groundbreaking results on how Cytox combines its comprehensive single nucleotide polymorphism (SNP) profiling assay with use of polygenic risk scoring (PRS) algorithms to stratify samples obtained from subjects who are pre-symptomatic or showing mild cognitive impairment (MCI) and are at risk of developing AD. Further, Cytox will describe two PRS algorithms optimised for identifying true amyloid positivity and true amyloid negativity, thus offering the potential to match performance to the specific needs of a clinical research study.
Richard Pither, CEO of Cytox, commented, “The presentation will highlight data obtained from over 1000 samples from multiple clinical research validation studies jointly run by Cytox and its global academic research collaborators, and represents follow-on efforts to the 2016 launch to early access sites of our solution. Cytox’s breakthrough approach interrogates over 130,000 SNP biomarkers found on the research use variaTECT™ array used in combination with analysis by our proprietary SNPfitR™ interpretive software for polygenic risk scoring for assessing AD onset risk, including those with negative ApoE4 genotypes. The test runs on the commercially proven Applied Biosystems™ GeneTitan™ Multi-Channel (MC) Instrument platform (for research use only) and is available globally as a service for early access collaborators.”
The presentation, “Identification of Amyloid Positive Individuals in MCI or Elderly Pre-Symptomatic Cohorts Using a Novel Panel”, will be given by Dr Maryam Shoai, UCL Institute of Neurology, London, United Kingdom at 16:15 - 16:30, as part of Symposium 31 – Genetics of AD, ALS and FTD, on Friday March 31, 14:45 - 16:45 in Hall B, the Austria Centre. The authors are Dr Maryam Shoai; Dr Richard Pither, Cytox Ltd, UK, Oxford, United Kingdom; Professor Valentina Escott-Price, Cardiff University, Cardiff, United Kingdom; Dr Simon M Laws, Edith Cowan University, and Cooperative Research Centre (CRC) for Mental Health, Perth, Australia; Julie Davis, MSc, Cytox Ltd, UK, Oxford, United Kingdom; Professor Harald Hampel, AXA Research Fund & UPMC Chair, Paris, France; Professor Rik Vandenberghe and Dr Isabelle Cleynen, Katholieke Universiteit Leuven, Leuven, Belgium; Dr Greg Davidson Ledcourt Associates, United Kingdom; Professor John Trojanowski, Professor Virginia Lee and Professor Vivianna Van Deerlin, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, USA; and Professor John Hardy, UCL Institute of Neurology, London, United Kingdom.
More information about the event can be found on the AD/PD Conference website http://adpd2017.kenes.com/.